BEDFORD, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Hologic, Inc.
(Nasdaq: HOLX) announced today that the FDA Obstetrics and Gynecology
Devices Advisory Panel recommended that the pre-market application for
Adiana(R) Permanent Contraception for female sterilization is Approvable.
The panel reached this decision by a vote of 10 to 3.
The FDA is not required to accept, but traditionally follows the
recommendations of its advisory panels. The panel recommended approval of
the device contingent upon several conditions, including long-term follow
up of current pivotal trial patients, a new post approval study of new
patients and physicians, and more specific labeling recommendations.
"Women are looking for choices for their long-term contraceptive
needs," said Ted Anderson, M.D., Ph.D., Associate Professor of Obstetrics
and Gynecology at Vanderbilt University Medical Center, and clinical
investigator of the pivotal clinical trial for Adiana. "Adiana provides a
novel, safe and effective permanent transcervical alternative to tubal
ligation. The procedure takes approximately 15 minutes to perform without
the risky and uncomfortable side effects experienced with a more invasive
surgical procedure but with comparable efficacy in avoiding pregnancy as
underscored by the results of the clinical trials where the device was
evaluated in more than 600 women."
Bilateral tubal ligation -- commonly referred to as "getting your tubes
tied" -- is the most common form of contraception used throughout the
world. Approximately 700,000(1) tubal ligation surgical procedures are
performed annually in the U.S. alone. The surgery is typically performed in
a hospital operating room under general anesthesia and requires the
physician to make one or two incisions in the abdomen. This usually
requires approximately four to five days of recuperation.
In contrast, Adiana is a minimally-invasive, non-incisional
alternative. This procedure uses hysteroscopy, generally requires only
local anesthesia, and can be performed in a physician's office. Patients
are typically able to return to work or resume their everyday activities
within a day.
"Contraception is obviously a critical decision for any woman," said
Sue Knapton, a 46-year-old woman who participated in the clinical trial of
Adiana. "This seemed to me to be the better choice than more invasive
surgery or long- term use of oral contraceptives. I am glad I was able to
participate in the Adiana trial and hope other women will benefit from
Adiana in the future."
"Today represents a tremendous milestone in enabling us to realize our
goal in making Adiana a viable and better alternative for women looking for
permanent contraception. We will work closely with the FDA to address any
remaining issues and expedite final approval. We are confidently on course
to provide women with an important new treatment option," said Tony
Kingsley, President, Hologic GYN Surgical Products.
The pivotal clinical trial to demonstrate the safety and effectiveness
of Adiana in providing permanent contraception was conducted in the U.S.,
Australia, and Mexico. As part of the clinical trial, 645 women between the
ages of 21 and 45 had treatment attempted with Adiana. The procedure showed
a strong safety profile, with very high device placement success, patient
tolerance, comfort and satisfaction. A pregnancy prevention efficacy rate
of 98.9 percent after 12 months of reliance on Adiana was demonstrated,
successfully meeting the trial's primary endpoint. This efficacy result
also compares favorably with the results of the CREST Study (U.S.
Collaborative Review of Sterilization), which examined the long-term
failure of tubal ligation for sterilization.
About Adiana Permanent Contraception
Adiana is a novel, two-step approach to permanent contraception. First,
a catheter is positioned immediately inside the opening of the patient's
fallopian tube using a hysteroscope, eliminating the need for any
incisions. The catheter applies a very low-level of bi-polar radiofrequency
(RF) energy to remove just a thin layer of cells that line a 1cm section of
the inside of the fallopian tube. The catheter then delivers an
implantable, soft polymer, called a "matrix," which remains within the
prepared section of the tube. The matrix is smaller than a grain of rice.
The procedure is then repeated on the other fallopian tube. Healthy tissue
will grow into the matrix, creating a complete blockage of each tube. A
confirmatory dye test called a hysterosalpingogram (HSG) is conducted at
three months post-procedure to ensure the fallopian tubes are completely
blocked and that the woman can begin relying on Adiana for permanent
About Hologic, Inc.
Hologic, Inc. is a diversified medical technologies company
specializing in diagnostic imaging products and interventional devices
dedicated to serving the healthcare needs of women. Historically, the
Company has developed, manufactured and marketed products focused on
mammography, breast care and osteoporosis assessment. In October 2007,
Hologic completed its business combination with Cytyc Corporation, a
company that develops, manufactures and markets complementary products
covering a range of cancers and women's health indications, including
cervical cancer screening, treatment of excessive menstrual bleeding,
prenatal diagnostics and partial breast radiation therapy.
This press release contains forward-looking information that involves
risks and uncertainties, including statements regarding Hologic's plans,
objectives, expectations and intentions. Such statements include, without
limitation, statements regarding the future approval by the FDA of the
premarket application for Adiana Permanent Contraception for female
sterilization and the benefits realizable by using the Adiana Permanent
Contraception procedure. The Company cannot assure when or if FDA approval
will be granted or that the anticipated efficacy of the Adiana Permanent
Contraception procedure will be realizable. Factors that could adversely
affect Hologic's business and prospects are described in the Company's
filings with the Securities and Exchange Commission. Hologic expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in the Company's
expectations or any change in events, conditions or circumstances on which
any such statement is based.
(1) Westhoff C, Davis A. Tubal sterilization: focus on the U.S.
experience. Fertil Steril. 2000;73(5):913-922.
Jane Hauser or Sarah Belkner
Director, Investor Relations
SOURCE Hologic, Inc.